These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

703 related articles for article (PubMed ID: 32321638)

  • 1. Inhibition of RIPK1/RIPK3 ameliorates osteoclastogenesis through regulating NLRP3-dependent NF-κB and MAPKs signaling pathways.
    Liang S; Nian Z; Shi K
    Biochem Biophys Res Commun; 2020 Jun; 526(4):1028-1035. PubMed ID: 32321638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
    Chen G; Xu Q; Dai M; Liu X
    Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of PFKFB3 suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss.
    Wang J; Guan H; Liu H; Lei Z; Kang H; Guo Q; Dong Y; Liu H; Sun Y; Fang Z; Li F
    J Cell Mol Med; 2020 Feb; 24(3):2294-2307. PubMed ID: 31880389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Licorice isoliquiritigenin-encapsulated mesoporous silica nanoparticles for osteoclast inhibition and bone loss prevention.
    Sun X; Zhang J; Wang Z; Liu B; Zhu S; Zhu L; Peng B
    Theranostics; 2019; 9(18):5183-5199. PubMed ID: 31410209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioactive iron oxide nanoparticles suppress osteoclastogenesis and ovariectomy-induced bone loss through regulating the TRAF6-p62-CYLD signaling complex.
    Liu L; Jin R; Duan J; Yang L; Cai Z; Zhu W; Nie Y; He J; Xia C; Gong Q; Song B; Anderson JM; Ai H
    Acta Biomater; 2020 Feb; 103():281-292. PubMed ID: 31866569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss.
    Zhu M; Liu H; Sun K; Liu J; Mou Y; Qi D; Zhou C; Abudunaibi M; Tasiken B; Li J; Cheng H; Huang H
    Biomed Pharmacother; 2020 Mar; 123():109769. PubMed ID: 31846839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways.
    Song J; Jing Z; Hu W; Yu J; Cui X
    Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of IL-6 and sIL-6R differentially regulate varying levels of RANKL-induced osteoclastogenesis through NF-κB, ERK and JNK signaling pathways.
    Feng W; Liu H; Luo T; Liu D; Du J; Sun J; Wang W; Han X; Yang K; Guo J; Amizuka N; Li M
    Sci Rep; 2017 Jan; 7():41411. PubMed ID: 28128332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways.
    Chen K; Yan Z; Wang Y; Yang Y; Cai M; Huang C; Li B; Yang M; Zhou X; Wei X; Yang C; Chen Z; Zhai X; Li M
    Biomed Pharmacother; 2020 Jun; 126():110067. PubMed ID: 32272431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
    Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
    Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
    Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-α signaling pathways.
    Li CH; Ma ZZ; Jian LL; Wang XY; Sun L; Liu XY; Yao ZQ; Zhao JX
    Int Immunopharmacol; 2021 Jan; 90():107219. PubMed ID: 33307512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Garcinol suppresses RANKL-induced osteoclastogenesis and its underlying mechanism.
    Jia Y; Jiang J; Lu X; Zhang T; Zhao K; Han W; Yang W; Qian Y
    J Cell Physiol; 2019 May; 234(5):7498-7509. PubMed ID: 30471112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhinacanthin C Inhibits Osteoclast Differentiation and Bone Resorption: Roles of TRAF6/TAK1/MAPKs/NF-κB/NFATc1 Signaling.
    Tomomura M; Suzuki R; Shirataki Y; Sakagami H; Tamura N; Tomomura A
    PLoS One; 2015; 10(6):e0130174. PubMed ID: 26083531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells-derived interferon-λ1 ameliorated inflammatory bone destruction through inhibiting osteoclastogenesis.
    Chen Y; Wang Y; Tang R; Yang J; Dou C; Dong Y; Sun D; Zhang C; Zhang L; Tang Y; Dai Q; Luo F; Xu J; Dong S
    Cell Death Dis; 2020 Jun; 11(6):414. PubMed ID: 32488049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
    Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dencichine prevents ovariectomy-induced bone loss and inhibits osteoclastogenesis by inhibiting RANKL-associated NF-κB and MAPK signaling pathways.
    Cang D; Zou G; Yang C; Shen X; Li F; Wu Y; Ji B
    J Pharmacol Sci; 2021 Aug; 146(4):206-215. PubMed ID: 34116734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.